Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: Methods and systems for creating a webpage having different element orders for different webpage widths are disclosed. A computing device receives inputs specifying different layouts of elements in different orders for different webpage widths. The computing device creates markup code for the webpage that specifies separate subtrees of nodes for the different layouts and then modifies the markup code to replace duplicate nodes with placeholders in the subtrees. The computing device also creates script code for the webpage with instructions for modifying a live DOM created from the markup code based on current webpage width. Specifically, the script code modifies the live DOM to specify positioning the elements differently for different webpage widths by changing the visibility of nodes and swapping placehoders and content nodes in the subtrees.

Abstract: Techniques for responsive design controls are described. A user interface is provided having a breakpoint bar configured to display multiple selectable breakpoints. When the breakpoints are selected, digital content displayed on a design surface located adjacent to the breakpoint bar is resized according to a relative size of the breakpoint. The user interface additionally has a central axis along which the multiple breakpoints are distributed. The design surface enables the digital content to be viewed and resized around the central axis responsive to selection of one of the breakpoints. Additional tools and techniques are provided to implement responsive design controls.

Abstract: Methods and systems for creating a webpage having different element orders for different webpage widths are disclosed. A computing device receives inputs specifying different layouts of elements in different orders for different webpage widths. The computing device creates markup code for the webpage that specifies separate subtrees of nodes for the different layouts and then modifies the markup code to replace duplicate nodes with placeholders in the subtrees. The computing device also creates script code for the webpage with instructions for modifying a live DOM created from the markup code based on current webpage width. Specifically, the script code modifies the live DOM to specify positioning the elements differently for different webpage widths by changing the visibility of nodes and swapping placehoders and content nodes in the subtrees.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract: A management user interface can be generated at run time via subtractive extensible context-based filtering. Definitions of user interface elements can include an indication of appropriate contexts for which the user interface elements are to be shown. Context factors can include application state, external state, surface or element definitions, or some combination thereof. The context-based filtering approach allows definition of user interface elements and user interface surfaces so that appearance of additional elements in the appropriate surfaces can be accomplished without programming. For example, a user interface surface definition can specify categories of user interface elements. At run time, those user interface elements of the category can be chosen for display. When new elements relating to the category are added, the new elements appear when the surface is rendered. Other features include heterogeneous type selection and exact number homogeneous type selection.